Prazosin for Disruptive Agitation in Alzheimer's Disease (PEACE-AD)

This is a Phase IIb multicenter, randomized, double-blind, placebocontrolled study evaluating the efficacy and safety of prazosin in approximately 186 Alzheimer’s disease (AD) participants with disruptive agitation in long-term care (LTC) The total active study duration is approximately 1.5 years, including start-up, recruitment and follow-up periods. The total duration of individual study participation is approximately 14 weeks. Individual study participation consists of the following: • Screening period up to 14 days. • Duration of treatment of 12 weeks.